These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38030336)

  • 21. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).
    Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N
    Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implant and clinical characteristics for pediatric and congenital heart patients in the national cardiovascular data registry implantable cardioverter defibrillator registry.
    Jordan CP; Freedenberg V; Wang Y; Curtis JP; Gleva MJ; Berul CI
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1092-100. PubMed ID: 25287482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.
    Basu-Ray I; Liu J; Jia X; Gold M; Ellenbogen K; DiNicolantonio J; Komócsi A; Vorobcsuk A; Kim J; Afshar H; Lam W; Mathuria N; Razavi M; Rasekh A; Saeed M
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1475-1483. PubMed ID: 29759827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M; Moore JP; Sreeram N; von Alvensleben JC; Shah A; Batra A; Law I; Sanatani S; Thomas V; Nik-Ahd F; Williams S; Nosavan N; Maldonado J; Hart A; Nguyen T; Balaji S
    Heart Rhythm; 2018 May; 15(5):703-707. PubMed ID: 29309839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implantable cardioverter-defibrillator therapy to reduce sudden cardiac death in adults with congenital heart disease: A registry study.
    Slater TA; Cupido B; Parry H; Drozd M; Blackburn ME; Hares D; Pepper CB; Birkitt L; Cullington D; Witte KK; Oliver J; English KM; Sengupta A
    J Cardiovasc Electrophysiol; 2020 Aug; 31(8):2086-2092. PubMed ID: 32583559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transvenous versus subcutaneous implantable cardioverter defibrillators in young cardiac arrest survivors.
    Morton MB; Mariani JA; Kistler PM; Patel H; Voskoboinik A
    Intern Med J; 2023 Nov; 53(11):1956-1962. PubMed ID: 37929818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting the right defibrillator in the younger patient: Transvenous, epicardial or subcutaneous?
    Bogush N; Espinosa RE; Cannon BC; Wackel PL; Okamura H; Friedman PA; McLeod CJ
    Int J Cardiol; 2018 Jan; 250():133-138. PubMed ID: 29169751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inappropriate ICD shocks in pediatrics and congenital heart disease patients: Risk factors and programming strategies.
    Garnreiter JM; Pilcher TA; Etheridge SP; Saarel EV
    Heart Rhythm; 2015 May; 12(5):937-42. PubMed ID: 25620047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eligibility for subcutaneous implantable cardioverter defibrillators in the adult congenital heart disease population.
    Garside H; Leyva F; Hudsmith L; Marshall H; de Bono J
    Pacing Clin Electrophysiol; 2019 Jan; 42(1):65-70. PubMed ID: 30394548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous and Transvenous ICDs: an Update on Contemporary Questions and Controversies.
    Friedman DJ; Tully AS; Zeitler EP
    Curr Cardiol Rep; 2022 Aug; 24(8):947-958. PubMed ID: 35639275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous implantable cardioverter defibrillator in children and adolescents: results from the S-ICD "Monaldi care" registry.
    Sarubbi B; Colonna D; Correra A; Romeo E; D'Alto M; Palladino MT; Virno S; D'Onofrio A; Russo MG
    J Interv Card Electrophysiol; 2022 Mar; 63(2):283-293. PubMed ID: 33709295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias.
    Raja J; Guice K; Oberoi M; Whitwell S; Asbeutah AA; Russell A; Khouzam RN
    Curr Probl Cardiol; 2022 Sep; 47(9):100927. PubMed ID: 34311985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death.
    Sanghera R; Sanders R; Husby M; Bentsen JG
    Ann N Y Acad Sci; 2014 Nov; 1329():1-17. PubMed ID: 25308791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping.
    Zeb M; Curzen N; Veldtman G; Yue A; Roberts P; Wilson D; Morgan J
    Europace; 2015 Jul; 17(7):1059-67. PubMed ID: 25678600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous implantable cardioverter defibrillators in children, young adults and patients with congenital heart disease.
    Bordachar P; Marquié C; Pospiech T; Pasquié JL; Jalal Z; Haissaguerre M; Thambo JB
    Int J Cardiol; 2016 Jan; 203():251-8. PubMed ID: 26519678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator.
    Silka MJ; Bar-Cohen Y
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):298-306. PubMed ID: 19808422
    [No Abstract]   [Full Text] [Related]  

  • 40. Subcutaneous Implantable Cardioverter Defibrillators: An Overview of Implantation Techniques and Clinical Outcomes.
    Al-Ghamdi B
    Curr Cardiol Rev; 2019; 15(1):38-48. PubMed ID: 30014805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.